Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedrich Scheiflinger

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
Molecular Therapy. Methods & Clinical Development|July 25, 2019
Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy DonorsAnita Kruzik, Damir Fetahagic, Bettina Hartlieb, et al.
Blood|October 24, 2002
Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)Barbara Plaimauer, Klaus Zimmermann, Dirk Völkel, et al.
British Journal of Haematology|May 19, 2004
Mutation of the surface-exposed amino acid Trp to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional proteinSimone M Schatz, Klaus Zimmermann, Meinhard Hasslacher, et al.
International Journal of Hematology|September 25, 2013
Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia BBarbara Dietrich, Alexandra Schiviz, Werner Hoellriegl, et al.
Pharmaceutical Research|June 9, 2016
The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?Christian Lubich, Peter Allacher, Maurus de la Rosa, et al.
Thrombosis and Haemostasis|February 24, 2006
Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA)Manfred Rieger, Silvia Ferrari, Johanna A Kremer Hovinga, et al.
Molecular Therapy. Methods & Clinical Development|March 24, 2025
Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIIIJohannes Lengler, Markus Weiller, Franziska Horling, et al.
Biochemistry|February 8, 2018
Role of the Cysteine 81 Residue of Macrophage Migration Inhibitory Factor as a Molecular Redox SwitchAlexander Schinagl, Randolf J Kerschbaumer, Nicolas Sabarth, et al.
Pharmaceutical Research|June 19, 2013
Development of a transgenic mouse model with immune tolerance for human coagulation factor VIIaChristine Lenk, Sabine Unterthurner, Maria Schuster, et al.
Molecular Cancer Therapeutics|April 27, 2013
Human anti-macrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells in vitro and in vivoFilza Hussain, Michael Freissmuth, Dirk Völkel, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
Molecular Therapy. Methods & Clinical Development|July 25, 2019
Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy DonorsAnita Kruzik, Damir Fetahagic, Bettina Hartlieb, et al.
Blood|October 24, 2002
Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13)Barbara Plaimauer, Klaus Zimmermann, Dirk Völkel, et al.
British Journal of Haematology|May 19, 2004
Mutation of the surface-exposed amino acid Trp to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional proteinSimone M Schatz, Klaus Zimmermann, Meinhard Hasslacher, et al.
International Journal of Hematology|September 25, 2013
Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia BBarbara Dietrich, Alexandra Schiviz, Werner Hoellriegl, et al.
Pharmaceutical Research|June 9, 2016
The Mystery of Antibodies Against Polyethylene Glycol (PEG) - What do we Know?Christian Lubich, Peter Allacher, Maurus de la Rosa, et al.
Thrombosis and Haemostasis|February 24, 2006
Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA)Manfred Rieger, Silvia Ferrari, Johanna A Kremer Hovinga, et al.
Molecular Therapy. Methods & Clinical Development|March 24, 2025
Preclinical development of TAK-754, a high-performance AAV8-based vector expressing coagulation factor VIIIJohannes Lengler, Markus Weiller, Franziska Horling, et al.
Biochemistry|February 8, 2018
Role of the Cysteine 81 Residue of Macrophage Migration Inhibitory Factor as a Molecular Redox SwitchAlexander Schinagl, Randolf J Kerschbaumer, Nicolas Sabarth, et al.
Pharmaceutical Research|June 19, 2013
Development of a transgenic mouse model with immune tolerance for human coagulation factor VIIaChristine Lenk, Sabine Unterthurner, Maria Schuster, et al.
Molecular Cancer Therapeutics|April 27, 2013
Human anti-macrophage migration inhibitory factor antibodies inhibit growth of human prostate cancer cells in vitro and in vivoFilza Hussain, Michael Freissmuth, Dirk Völkel, et al.
Pageof 9